THU073 Somapacitan Administered Subcutaneously At 5 mg/1.5 mL Or 10 mg/1.5 mL Strengths Yields Clinically Similar PK And IGF-I Profiles In Healthy Participants

Disclosure: M. Højby Rasmussen: Employee; Self; Novo Nordisk. Stock Owner; Self; Novo Nordisk. R.J. Kildemoes: Employee; Self; Novo Nordisk. Stock Owner; Self; Novo Nordisk. C. Sværke: Employee; Self; Novo Nordisk. Stock Owner; Self; Novo Nordisk. Background: Somapacitan is a once-weekly long-acting...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasmussen, Michael Højby, Kildemoes, Rasmus J, Sværke, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Neuroendocrinology And Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555757/
http://dx.doi.org/10.1210/jendso/bvad114.1153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555757/
http://dx.doi.org/10.1210/jendso/bvad114.1153

Ejemplares similares